23
Participants
Start Date
February 27, 2019
Primary Completion Date
August 14, 2020
Study Completion Date
October 30, 2021
tisotumab vedotin
Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
National Cancer Center Hosptial East, Kashiwa-shi
NHO Shikoku Cancer Center, Matsuyama
NHO Hokkaido Cancer Center, Sapporo
Kanagawa Cancer Center, Yokohama
Saitama Medical University International Medical Center, Hidaka-shi
Shizuoka Cancer Center, Sunto-gun
National Cancer Center Hospital, Chūōku
Keio University Hospital, Shinjuku-ku
Lead Sponsor
Seagen Inc.
INDUSTRY
Genmab
INDUSTRY